Galectin Therapeutics Inc. (GALT)
NASDAQ: GALT · Real-Time Price · USD
2.190
-0.370 (-14.45%)
At close: Apr 7, 2026, 4:00 PM EDT
2.360
+0.170 (7.76%)
After-hours: Apr 7, 2026, 7:54 PM EDT

Galectin Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-30.84-47.05-41.07-38.78-30.53
Depreciation & Amortization
0.050.040.030.030.04
Stock-Based Compensation
1.662.452.262.872.08
Other Adjustments
10.884.953.230.480.35
Changes in Other Operating Activities
-5.63-2.162.584.353.75
Operating Cash Flow
-23.88-41.77-32.97-31.06-24.31
Long-Term Debt Issued
2130301030
Net Long-Term Debt Issued (Repaid)
2130301030
Issuance of Common Stock
5.481.2310.03-6.81
Net Common Stock Issued (Repurchased)
5.481.2310.03-6.81
Financing Cash Flow
26.4831.2340.031036.81
Net Cash Flow
2.6-10.547.07-21.0612.51
Free Cash Flow
-23.88-41.77-32.97-31.06-24.31
Free Cash Flow Per Share
-0.37-0.67-0.55-0.52-0.42
Levered Free Cash Flow
-15.55-19.32-12.19-24.53.09
Unlevered Free Cash Flow
-25.66-44.55-35.46-33.98-26.39
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q